Back to Trials
NCT06892704Recruiting

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

Northwestern University

Start Date

5/1/2025

Completion Date

12/31/2027

Summary

The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell? Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.

Eligibility Criteria

Age Range: 18 years to 65 years

* Well documented history of CRSwNP * BSIT age/sex classified as "abnormal" score * Self-reported stable olfactory deficit of moderate to severe quality \> 3 months * Prior endoscopic sinus surgery \>3 months, \<10 years prior

Interventions

DRUG

Dupilumab - Standard Dose

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)Smell Loss

Locations

Northwestern University Feinberg School of Medicine

Chicago, Illinois 60611

United States